DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author(s): Dr Kate Dear, Dermatology Research Fellow, Skin Health Institute, Melbourne, Australia. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. October 2020.
Schöpf-Schulz-Passarge syndrome (SSPS) is a form of ectodermal dysplasia.
Ectodermal dysplasias are a group of inherited disorders which show similar features of developmental abnormalities in two or more of the following structures: hair, teeth, nails, sweat glands, and other ectodermal-derived structures.
SSPS was first reported in 1971 and subsequently named for the three German dermatologists and geneticists who described the characteristic features in two sisters born of a consanguineous marriage. It is rare with less than 50 cases reported in the literature.
Schöpf-Schulz-Passarge syndrome has been linked to mutations in the WNT10A gene on chromosome 2, which are also observed in odonto-onycho-dermal dysplasia, hypohidrotic ectodermal dysplasia, and isolated hypodontia. There is thought to be some overlap with these conditions, however apocrine hidrocystomas of the eyelids are unique to SSPS. To date, 11 different mutations in the WNT10A gene have been linked to SSPS. The WNT10A gene encodes a protein involved in the development and regulation of ectodermal tissue.
Schöpf-Schulz-Passarge syndrome is an autosomal recessive genetic condition, meaning two faulty copies of the gene (ie, one from each parent) are needed for the condition to occur. However, individuals who are heterozygous with one faulty copy of the WNT10A gene may also show hair, nail, skin, or teeth abnormalities.
Cutaneous features of Schöpf-Schulz-Passarge syndrome typically do not present in childhood, starting to appear in the early teenage years and becoming more obvious with age. These can include the following features:
Non-cutaneous features of SSPS include:
Complications of SSPS include skin fragility, pain, and cosmetic disfigurement. With age, many of the features of SSPS become more troublesome and eyelid cysts become larger and more numerous. Secondary teeth may be abnormal or never erupt.
The risk of SSPS patients developing cancer is controversial, but there may be an increased risk of benign and malignant skin tumours, including squamous cell carcinoma, basal cell carcinoma, eccrine porocarcinoma, and multiple eccrine syringofibroadenomas. Skin surveillance is therefore essential.
Early diagnosis is rare because the cardinal feature, eyelid cysts, appear at a mean age of 50 years and are asymptomatic. This results in a mean age of diagnosis at 60 years, despite other clinical features presenting earlier in life. It is primarily a clinical diagnosis that does not require further tests, however genetic testing can be arranged.
Differential diagnoses for SSPS include other ectodermal dysplasias, such as:
There is no curative treatment for SSPS. Therapy is aimed at symptom management. Suggested therapies include:
The life expectancy for patients with SSPS is normal.
With advancing age, many of the features become more troublesome, and apocrine hidrocystomas become larger and more numerous.
Books about skin diseases
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.